In this episode, Mercatus Research Fellow Satya Marar speaks with Tomas Philipson, former Acting Chair of the Council of Economic Advisers and Professor at the University of Chicago, about the evidence behind drug price controls and their effects on healthcare affordability, pharmaceutical innovation, and research and development. They discuss the economics of patented and generic drugs, the Inflation Reduction Act, Most-Favored-Nation drug pricing proposals, and why policies intended to lower drug prices may ultimately reduce innovation and increase long-term healthcare costs. This episode features audio from a recent Mercatus webinar.

If you would like to connect with a scholar featured in this episode, please email the Mercatus Outreach team at mercatusoutreach@mercatus.gmu.edu.

Read a full transcript of the conversation: https://www.mercatus.org/economic-insights/event-videos/right-diagnosis-wrong-cure-examining-true-cost-drug-price-controls

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Mercatus Center at George Mason University. Innehållet i podden är skapat av Mercatus Center at George Mason University och inte av, eller tillsammans med, Poddtoppen.